{"id":"W4399361514","doi":"10.1016/j.esmoop.2024.103466","title":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; Chugai Pharmaceutical; Seagen; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Novartis; Daiichi-Sankyo; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Palbociclib; Hormone receptor; Docetaxel; Gynecology; Chemotherapy; Cancer; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007579579,0.0007354046,0.001819379,0.0006678409,0.0003373715,0.001047669,0.0004066454,0.0006099058,0.002244723],"category_scores_gemma":[0.001063856,0.0003661685,0.003572496,0.0007863767,0.0002611276,0.000460571,0.0004817021,0.0008688184,0.0002118141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005364333,"about_ca_system_score_gemma":0.000710925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001598055,"about_ca_topic_score_gemma":0.003624873,"domain_scores_codex":[0.9994086,0.0001774345,0.0000764845,0.0001493156,0.00005968463,0.0001285382],"domain_scores_gemma":[0.9995717,0.0001282514,0.000108871,0.00005443726,0.00002386485,0.0001128216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.281332,0.001955159,0.6494372,0.0007496897,0.01654879,0.001093359,0.0002870793,0.0008666477,0.007875096,0.0001434291,0.001455259,0.03825626],"study_design_scores_gemma":[0.01601079,0.01666256,0.9473333,0.0001343728,0.01165147,0.001131905,0.0005591424,0.001984671,0.001200045,0.0003877394,0.002870784,0.00007321498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958442,0.002850584,0.0001074605,0.00007928059,0.00003419057,0.0001224033,0.0005169115,0.000004970353,0.0004400414],"genre_scores_gemma":[0.997795,0.0005910603,0.0001086223,0.0001127837,0.00005890118,0.0001165668,0.0009005917,0.000004712635,0.0003117774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002244723,"threshold_uncertainty_score":0.007509291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009595296794721674,"score_gpt":0.2882959797367978,"score_spread":0.2787006829420762,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}